Parameter | n (%) | Overall survival | |
---|---|---|---|
 |  | p-value (log rank) | HR (CI), p-value |
Membranous EGFR | 121 (100) | 0.002 | 2.8 (1.4-5.6), 0.004 |
positive | 44 (36.4) | Â | Â |
negative | 77 (63.6) | Â | Â |
Cytoplasmic EGFR | 121 (100) | 0.79 | 0.9 (0.4-1.8), 0.79 |
positive | 81 (66.9) | Â | Â |
negative | 40 (33.1) | Â | Â |
Age at surgery (years) | 121 (100) | 0.003 | 2.8 (1.3-5.7), 0.004 |
< 60 | 73 (60.3) | Â | Â |
≥ 60 | 48 (39.7) |  |  |
Histological type | 121 (100) | 0.71 | 1.1 (0.7-1.9), 0.68 |
serous | 80 (66.1) | Â | Â |
non-serous | 29 (24.0) | Â | Â |
undifferentiated | 12 (9.9) | Â | Â |
FIGO stage | 121 (100) | 0.44 | 1.5 (0.9-2.5), 0.13 |
I | 18 (14.9) | Â | Â |
II | 10 (8.3) | Â | Â |
III | 84 (69.4) | Â | Â |
IV | 9 (7.4) | Â | Â |
Tumor stage | 121 (100) | 0.14 | 1.6 (0.9-2.9), 0.08 |
pT1 | 21 (17.3) | Â | Â |
pT2 | 12 (10.0) | Â | Â |
pT3 | 88 (72.7) | Â | Â |
Nodal stage | 96 (100) | 0.05 | 2.7 (0.9-7.8), 0.06 |
pN0 | 46 (47.9) | Â | Â |
pN1 | 50 (52.1) | Â | Â |
Tumor grade | 121 (100) | 0.035 | 2.0 (1.1-3.5), 0.013 |
G1 | 19 (15.7) | Â | Â |
G2 | 50 (41.3) | Â | Â |
G3 | 52 (43.0) | Â | Â |
Intraoperative residual tumor | 88 (100) | 0.0001 | 5.0 (1.9-13.0), 0.001 |
residual tumor < 2 cm | 78 (88.6) | Â | Â |
residual tumor ≥ 2 cm | 10 (11.4) |  |  |